Osteoarthritis and Cartilage | February 12, 2021
-
A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis
Osteoarthritis and Cartilage. doi: 10.1016/j.joca.2021.02.004
Yusuf Yazici, MD, Timothy E. McAlindon, MD, MPH, Allan Gibofsky, MD, JD, Nancy E. Lane, MD, Christian Lattermann, MD, Nebojsa Skrepnik, MD, PhD, Christopher J. Swearingen, PhD, Ismail Simsek, MD, Heli Ghandehari, MS, Anita DiFrancesco, BS, BA, Jamielle Gibbs, MPH, Jeyanesh Tambiah, MD, Marc C. Hochberg, MD, MPH
Article
American College of Rheumatology (ACR) Convergence | November 02 - 05, 2020
Virtual Meeting
-
The Patient Journey in Knee OA: Variations in Patient Characteristics and Treatment by Physician Specialty
Poster
-
Patient Characteristics and Factors Affecting Decision-Making Regarding Total Knee Replacement by Different Types of Physicians Treating Patients with Knee OA
Poster
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases | August 20 - 22, 2020
Virtual Meeting
-
Items Driving WOMAC Pain Subscore Changes Due to Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis: A Post Hoc Analysis of Phase 2b Trial Data
Poster
Journal of Medical Economics | August 13, 2020
-
Health care resource utilization and burden of disease in a U.S. Medicare population with a principal diagnosis of osteoarthritis of the knee
Journal of Medical Economics. doi: 10.1080/13696998.2020.1801453
Fang Chen, Wenqing Su, Angela V. Bedenbaugh & Arman Oruc
Article
European League Against Rheumatism (EULAR) | June 03 - 06, 2020
Virtual Meeting
-
Safety Profile of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Slides
-
Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK1A Inhibitor that Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries
Abstract
Arthritis & Rheumatology | May 20, 2020
-
Lorecivivint, a Novel Intra‐articular CLK/DYRK1A Inhibitor and Wnt Pathway Modulator for Treatment of Knee Osteoarthritis: A Phase 2 Randomized Trial
Arthritis & Rheumatology. doi: 10.1002/art.41315
Yusuf Yazici, Timothy E. McAlindon, Allan Gibofsky, Nancy E. Lane, Daniel Clauw, Morgan Jones, John Bergfeld, Christopher J. Swearingen, Anita DiFrancesco, Ismail Simsek, Jeyanesh Tambiah, Marc C. Hochberg
Article
European Workshop for Rheumatology Research (EWRR) | February 13 - 15, 2020
Leuven, Belgium
-
Lorecivivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants
Poster
American College of Rheumatology (ACR) | November 08 - 13, 2019
Atlanta, GA
-
Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation
Slides
-
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Poster
-
Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Poster
Cartilage Regeneration & Joint Preservation Society (ICRS) World Congress | October 05 - 08, 2019
Vancouver, Canada
-
Wnt Pathway Modulation via CLK2 and DYRK1A Inhibition by Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis
Slides
-
Prospective Comparison of Sham vs. Placebo Injections: Data from a Trial of Lorecivivint, a Wnt Pathway Inhibitor for Knee Osteoarthritis
Slides
Gordon Research Conference (GRC) - Wnt Signaling Networks in Development, Disease and Regeneration | August 11 - 16, 2019
Mount Snow, VT
-
Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation
Poster
European League Against Rheumatism (EULAR) | June 12 - 15, 2019
Madrid, Spain
-
Comparison of Knee Osteoarthritis Treatment Patterns by Rheumatologists vs. Other Providers in a U.S. Administrative Claims Database
Poster
-
Efficacy and Safety from a Phase 2b Trial of Lorecivivint (SM04690), a Novel Intra-articular Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
Poster
Osteoarthritis and Cartilage | May 24, 2019
-
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment
Osteoarthritis and Cartilage. doi: 10.1016/j.joca.2019.05.006
V. Deshmukh, A.L. O'Green, C. Bossard, T. Seo, L. Lamangan, M. Ibanez, A. Ghias, C. Lai, L. Do, S. Cho, J. Cahiwat, K. Chiu, M. Pedraza, S. Anderson, R. Harris, L. Dellamary, S. KC, C. Barroga, B. Melchior, B. Tam, S. Kennedy, J. Tambiah, J. Hood, Y. Yazici
Article
International Society for Pharmaeconomics and Outcomes Research (ISPOR) | May 18 - 22, 2019
New Orleans, LA
-
An Analysis of Treatment Patterns in Knee Osteoarthritis in a U.S. Administrative Claims Database
Poster
Academy of Managed Care Pharmacy (AMCP) | March 25 - 28, 2019
San Diego, CA
-
An Analysis of the Burden of Illness and Treatment in Knee Osteoarthritis in a U.S. Administrative Claims Database
Poster
American Academy of Orthopaedic Surgeons (AAOS) | March 12 - 16, 2019
Las Vegas, NV
-
A 52-Week, Randomized, Double-Blind, Phase 2 Study of an Intra-articular Wnt Pathway Inhibitor (SM04690) for Osteoarthritis
Poster
Orthopaedic Research Society (ORS) | February 02 - 05, 2019
Austin, TX
-
SM04690, a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Functions Through Inhibition of CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation
Poster
International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit | January 17 - 18, 2019
San Diego, CA
-
Efficacy and Safety from a Phase 2b Trial of SM04690: A Novel, Intra-Articular Wnt Pathway Inhibitor for the Treatment of Knee Osteoarthritis
Poster
American College of Rheumatology (ACR) | October 19 - 24, 2018
Chicago, IL
-
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
Poster
-
Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis
Poster
Asia Pacific League of Associations for Rheumatology (APLAR) | September 06 - 09, 2018
Kaohsiung, Taiwan
-
Results from a 52-week, phase 2a study of an intra-articular, small molecule Wnt pathway inhibitor, SM04690, for knee osteoarthritis
Slides
European League Against Rheumatism (EULAR) | June 13 - 16, 2018
Amsterdam, Netherlands
-
Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a Wnt pathway inhibitor, SM04690, for knee osteoarthritis treatment
Poster
-
Potential Nociceptive Pain Relief of Intra-Articular Saline Control in Clinical Trials of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Trials
Poster
-
Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52 week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor
Slides
Osteoarthritis Research Society International (OARSI) World Congress | April 26 - 29, 2018
Liverpool, United Kingdom
-
Radiographic Outcomes Were Concordant with Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) Strict Response: Post-Hoc Analysis from a Phase 2 Study of a Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment
Poster
-
Joint Space Width Inclusion Criteria Can Reduce Knee Osteoarthritis Trial Heterogeneity: Post-Hoc Data from a Phase 2 Trial of Wnt Pathway Inhibitor, SM04690
Poster
World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases | April 19 - 22, 2018
Krakow, Poland
-
SM04690, a small molecule Wnt pathway inhibitor, appeared to have no deleterious effects on bone, joint, and tissue health in knee OA models
Poster
-
SM04690 caused dose-dependent Wnt pathway modulation within a homeostatic range in a rat model of knee osteoarthritis
Poster
International Cartilage Repair Society (ICRS) | April 09 - 12, 2018
Macao, China
-
A 52 Week Randomized, Double-Blind Phase 2 Study of Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Osteoarthritis
Slides
-
Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: P2 Post-Hoc Data from Wnt Pathway Inhibitor, SM04690
Slides
-
Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment
Slides
-
SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models
Slides
American College of Rheumatology (ACR) | November 03 - 08, 2017
San Diego, CA
-
Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis
Slides
-
Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway
Inhibitor in Knee Osteoarthritis
Poster
Osteoarthritis and Cartilage | September 15, 2017
-
A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee
Osteoarthritis and Cartilage. doi: 10.1016/j.joca.2017.08.015
V. Deshmukh, H. Hu, C. Barroga, C. Bossard, S. KC, L. Dellamary, J. Stewart, K. Chiu, M. Ibanez, M. Pedraza, T. Seo, L. Do, S. Cho, J. Cahiwat, B. Tam, J.R.S. Tambiah, J. Hood, N.E. Lane, Y. Yazici
Article
Gordon Research Conference: Wnt Signaling | August 06 - 11, 2017
Stowe, VT
-
Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis
Poster - Slides
Osteoarthritis and Cartilage | July 13, 2017
-
A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study
Osteoarthritis and Cartilage, 25(10), 1598-1606. doi: 10.1016/j.joca.2017.07.006
Y. Yazici, T.E. McAlindon, R. Fleischmann, A. Gibofsky, N.E. Lane, A.J. Kivitz, N. Skrepnik, E. Armas, C.J. Swearingen, A. DiFrancesco, J.R.S. Tambiah, J. Hood, M.C. Hochberg
Article
International Cartilage Repair Society Heritage Summit | June 29 - Jul 01, 2017
Gothenburg, Sweden
-
Cartilage Regeneration in a Rat Model of Knee OA by SM04690, a Potential Disease Modifying Wnt Pathway Inhibitor
Poster
European League Against Rheumatism (EULAR) | June 14 - 17, 2017
Madrid, Spain
-
Clinical Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis: Week 26 Interim Analysis
Poster
-
Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Week 26 Interim Analysis
Slides
International Society for Pharmacoeconomics and Outcomes (ISPOR) | May 20 - 24, 2017
Boston, MA
-
A Statistical Analysis Plan to Understand Osteoarthritis Patient Journey by Linking Medicare Claims Across Care Delivery Settings
Poster
-
Health Care Resource Use of Medicare Beneficiaries With Primary Osteoarthritis (OA) Of The Knee – A Claims Data Analysis
Poster
Osteoarthritis Research Society International (OARSI) | April 27 - 30, 2017
Las Vegas, NV
-
Anti-inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis
Poster
American College of Rheumatology (ACR) | November 11 - 16, 2016
Washington D.C.
-
A Small Molecule, SM04690, has Inhibitory Effects on the Wnt Pathway and Inflammation In Vitro, With Potential Implications For the Treatment of Osteoarthritis
Poster
Royal Society of Medicine's 13th Medical Innovations Summit | September 17, 2016
London, United Kingdom
-
Samumed's Regenerative Medicine Platform
Slides
Osteoarthritis Research Society International (OARSI) | March 31 - Apr 03, 2016
Amsterdam, Netherlands
-
OMERACT-OARSI ‘Strict Responders’ Analysis from Results of a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of a Novel, Intra-Articular, Injectable Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Poster
-
Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis
Slides
American College of Rheumatology (ACR) | November 06 - 11, 2015
San Francisco, CA
-
Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Abstract - Poster
-
Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study
Abstract - Poster
-
Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis
Abstract - Slides
Award Winning